Vertex to acquire Crinetics for $85/share in $10B deal

MarketBeat Sat, July 11, 2026 at 2:02 PM PDT | 7 min read

• VRTX -2.24%
• CRNX -0.05%

Key Points

• Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10 billion in equity value ($8.8 billion net of cash). Vertex describes the acquisition as a strategic move to build an endocrinology franchise and expects to close in Q3 2026.
• The deal centers on two endocrine assets Vertex believes could generate over $5 billion in combined peak annual sales: PALSONIFY, an approved once-daily oral therapy for acromegaly, and atumelnant, a late-stage treatment for congenital adrenal hyperplasia (CAH). Vertex highlighted strong early PALSONIFY uptake and progress in payer coverage.
• Vertex plans to finance the purchase with cash and debt, including $4.5 billion in committed bridge financing. Management stated the acquisition should have a modest near-term financial impact and become accretive to non-GAAP operating income by 2029, while noting some development and safety risks remain for atumelnant.

Vertex's Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals (NASDAQ: VRTX) announced it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash — a transaction Vertex executives described as a strategic expansion into specialty endocrinology.

On a conference call announcing the deal, Vertex CEO and President Dr. Reshma Kewalramani said the transaction has a total equity value of approximately $10 billion, or $8.8 billion net of estimated cash acquired. She noted that Crinetics brings two lead endocrine assets that Vertex believes could generate more than $5 billion in combined peak annual sales:

• PALSONIFY — an approved oral therapy for acromegaly
• Atumelnant — an investigational therapy in pivotal development for congenital adrenal hyperplasia (CAH)

"Crinetics is an excellent strategic fit for Vertex," Kewalramani said, citing the company's focus on serious diseases, specialty markets, well-understood biology, and potentially best-in-class medicines.

PALSONIFY Seen as Blockbuster Opportunity

Kewalramani stated that PALSONIFY is the first and only once-daily oral therapy for adults with acromegaly, a rare hormonal disorder caused by excess growth hormone. The drug was launched in the U.S. in October 2025 and was more recently approved by the European Medicines Agency.

Vertex executives emphasized that many patients with acromegaly continue to need lifelong medical therapy after surgery. Current injectable somatostatin receptor ligands can be inconvenient, painful, and associated with low patient compliance.

Phase 3 Data Highlights

• 83% of patients switching from injectable therapies maintained IGF-1 levels within the normal range on PALSONIFY, compared with 4% on placebo.
• In a separate study including treatment-naive patients and those who had stopped prior treatment, 56% of PALSONIFY-treated patients achieved IGF-1 normalization, compared with 5% on placebo.

Duncan McKechnie, Vertex's Executive Vice President and Chief Commercial Officer, said PALSONIFY generated $10.3 million in net product revenue in the first quarter of 2026, based on data previously disclosed by Crinetics. He noted the product achieved a 40% to 50% share of new-to-brand prescriptions in its second quarter of launch, with uptake across pituitary centers and community endocrinologists.